

## HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use VIIBRYD® safely and effectively. See full prescribing information for VIIBRYD.

VIIBRYD® (vilazodone HCl) Tablets for oral administration  
Initial U.S. Approval: 2011

### WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

See full prescribing information for complete boxed warning.

- Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants (5.1).
- Monitor for worsening and emergence of suicidal thoughts and behaviors (5.1)
- VIIBRYD is not approved for use in pediatric patients (8.4).

### RECENT MAJOR CHANGES

Boxed Warning	12/2013
Dosage and Administration (2.3)	12/2013
Warnings and Precautions (5.2)	04/2014

### INDICATIONS AND USAGE

VIIBRYD is indicated for the treatment of major depressive disorder (MDD). The efficacy of VIIBRYD was established in two 8-week, placebo-controlled trials in adult patients with MDD (1, 14).

### DOSAGE AND ADMINISTRATION

- The recommended dose for VIIBRYD is 40 mg once daily (2.1).
- VIIBRYD should be titrated to the 40 mg dose, starting with an initial dose of 10 mg once daily for 7 days, followed by 20 mg once daily for an additional 7 days, and then increased to 40 mg once daily (2.1).
- VIIBRYD should be taken with food. Administration without food can result in inadequate drug concentrations and may diminish effectiveness (2.1, 12.3).
- When discontinuing treatment, reduce the dose gradually (2.4).

### DOSAGE FORMS AND STRENGTHS

VIIBRYD is available as 10 mg, 20 mg and 40 mg tablets (3).

### CONTRAINDICATIONS

- **Serotonin Syndrome and MAOIs:** Do not use MAOIs intended to treat psychiatric disorders with VIIBRYD or within 14 days of stopping treatment with VIIBRYD. Do not use VIIBRYD within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start VIIBRYD in a patient who is being treated with linezolid or intravenous methylene blue (4.1).

### WARNINGS AND PRECAUTIONS

- **Suicidal Thoughts and Behaviors in Children, Adolescents and Young Adults:** Monitor patients for clinical worsening and suicidal thinking or behavior (5.1).
- **Serotonin Syndrome:** Serotonin syndrome has been reported with SSRIs and SNRIs, including VIIBRYD, both when taken alone, but

especially when co-administered with other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone and St. John's Wort). If such symptoms occur, discontinue VIIBRYD and initiate supportive treatment. If concomitant use of VIIBRYD with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases (5.2).

- **Seizures:** Can occur with treatment. Use with caution in patients with a seizure disorder (5.3).
- **Abnormal Bleeding:** Treatment can increase the risk of bleeding. Use with caution in association with nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, or other drugs that affect coagulation (5.4).
- **Activation of Mania/Hypomania:** Can occur with treatment. Screen patients for bipolar disorder (5.5).
- **Discontinuation of Treatment with VIIBRYD:** A gradual reduction in dose is recommended rather than an abrupt cessation (5.6).
- **Hyponatremia:** Can occur in association with the syndrome of inappropriate antidiuretic hormone secretion (SIADH) (5.7).

### ADVERSE REACTIONS

The most common adverse reactions (incidence  $\geq$  5% and at least twice the rate of placebo) are: diarrhea, nausea, vomiting, and insomnia (6).

To report SUSPECTED ADVERSE REACTIONS, contact Forest Laboratories, Inc. at 1-800-678-1605 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

### DRUG INTERACTIONS

- **MAOIs:** Do not use VIIBRYD concomitantly with an MAOI or within 14 days of stopping or starting an MAOI (4.1, 7.2).
- **CYP3A4 inhibitors:** The VIIBRYD dose should be reduced to 20 mg when co-administered with CYP3A4 strong inhibitors (2.3, 7.5).
- **CYP3A4 inducers:** Based on clinical response, consider increasing the dose of VIIBRYD up to 2-fold when used concomitantly with strong CYP3A4 inducers (e.g., carbamazepine) for greater than 14 days. The maximum daily dose should not exceed 80 mg. (2.3, 7.5).

### USE IN SPECIFIC POPULATIONS

- **Pregnancy:** There are no controlled human data regarding VIIBRYD use during pregnancy. Use only if the potential benefits outweigh the potential risks (8.1).
- **Nursing Mothers:** There are no human data regarding VIIBRYD concentrations in breast milk. Women should breast feed only if the potential benefits outweigh the potential risks (8.3).
- **Pediatric Use:** The safety and efficacy of VIIBRYD in pediatric patients have not been studied (8.4).
- **Geriatric Use:** No dose adjustment is recommended on the basis of age (8.5).

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 04/2014

## FULL PRESCRIBING INFORMATION: CONTENTS\*

### WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

#### 1 INDICATIONS AND USAGE

#### 2 DOSAGE AND ADMINISTRATION

- 2.1 Initial Treatment of Major Depressive Disorder
- 2.2 Maintenance/Continuation/Extended Treatment
- 2.3 Concomitant Use of CYP3A4 Inhibitors or CYP3A4 Inducers
- 2.4 Discontinuing Treatment
- 2.5 Switching a Patient To or From a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders
- 2.6 Use of VIIBRYD with Other MAOIs such as Linezolid or Methylene Blue

#### 3 DOSAGE FORMS AND STRENGTHS

#### 4 CONTRAINDICATIONS

- 4.1 Monoamine Oxidase Inhibitors (MAOIs)

#### 5 WARNINGS AND PRECAUTIONS

- 5.1 Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults
- 5.2 Serotonin Syndrome
- 5.3 Seizures
- 5.4 Abnormal Bleeding
- 5.5 Activation of Mania/Hypomania
- 5.6 Discontinuation of Treatment with VIIBRYD
- 5.7 Hyponatremia

#### 6 ADVERSE REACTIONS

- 6.1 Clinical Studies Experience
- 6.2 Post-marketing Experience

#### 7 DRUG INTERACTIONS

- 7.1 Central Nervous System (CNS)-Active Agents
- 7.2 Monoamine Oxidase Inhibitors (MAOIs)
- 7.3 Serotonergic Drugs
- 7.4 Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin)
- 7.5 Potential for Other Drugs to Affect Vilazodone

7.6 Potential for Vilazodone to Affect Other Drugs

7.7 Drugs Highly Bound to Plasma Protein

7.8 Triptans

7.9 Alcohol

#### 8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Labor and Delivery

8.3 Nursing Mothers

8.4 Pediatric Use

8.5 Geriatric Use

8.6 Hepatic Impairment

8.7 Renal Impairment

8.8 Gender Effect

#### 9 DRUG ABUSE AND DEPENDENCE

9.1 Controlled Substance

9.2 Abuse and Dependence

#### 10 OVERDOSAGE

10.1 Human Experience

10.2 Management of Overdose

#### 11 DESCRIPTION

#### 12 CLINICAL PHARMACOLOGY

12.1 Mechanism of action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

#### 13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

#### 14 CLINICAL STUDIES

#### 16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

16.2 Storage

#### 17 PATIENT COUNSELING INFORMATION

17.1 Information for Patients

17.2 Medication Guide

\*Sections or subsections omitted from the full prescribing information are not listed

## FULL PRESCRIBING INFORMATION

### **WARNING: SUICIDAL THOUGHTS AND BEHAVIORS**

**Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see Warnings and Precautions (5.1)].**

**In patients of all ages who are started on antidepressant therapy, monitor closely for clinical worsening and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see Warnings and Precautions (5.1)].**

**VIIBRYD is not approved for use in pediatric patients [see Use in Specific Populations (8.4)].**

## **1 INDICATIONS AND USAGE**

VIIBRYD<sup>®</sup> is indicated for the treatment of major depressive disorder (MDD). The efficacy of VIIBRYD was established in two 8-week, randomized, double-blind, placebo-controlled trials in adult patients with a diagnosis of MDD [see *Clinical Studies (14)*].

Major depressive disorder consists of one or more major depressive episodes. A major depressive episode (DSM-IV-TR) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation.

## **2 DOSAGE AND ADMINISTRATION**

### **2.1 Initial Treatment of Major Depressive Disorder**

The recommended dose for VIIBRYD is 40 mg once daily. VIIBRYD should be titrated, starting with an initial dose of 10 mg once daily for 7 days, followed by 20 mg once daily for an additional 7 days, and then an increase to 40 mg once daily. VIIBRYD should be taken with food. VIIBRYD blood concentrations (AUC) in the fasted state can be decreased by approximately 50% compared to the fed state, and may result in diminished effectiveness in some patients [see *Clinical Pharmacology (12.3)*].

### **2.2 Maintenance/Continuation/Extended Treatment**

The efficacy of VIIBRYD has not been systematically studied beyond 8 weeks. It is generally agreed that acute episodes of major depressive disorder require several months or longer of sustained pharmacologic therapy. Patients should be reassessed periodically to determine the need for maintenance treatment and the appropriate dose for treatment.

### **2.3 Concomitant Use of CYP3A4 Inhibitors or CYP3A4 Inducers**

*Patients receiving concomitant CYP3A4 inhibitors:*

Reduce the VIIBRYD dose to 20 mg if co-administered with a strong inhibitor of CYP3A4 (e.g., ketoconazole). During co-administration with moderate inhibitors of CYP3A4 (e.g., erythromycin), the VIIBRYD dose should be reduced to 20 mg for patients with intolerable adverse events. The VIIBRYD dose should be readjusted to the original level when CYP3A4 inhibitors are discontinued [see *Drug Interactions (7.5)*].

*Patients receiving concomitant CYP3A4 inducers:*

Based on clinical response, consider increasing the dose of VIIBRYD up to 2-fold when concomitantly used with strong CYP3A4 inducers (e.g., carbamazepine) for greater than 14 days. The maximum daily dose should not exceed 80 mg. If CYP3A4 inducers are discontinued, reduce the VIIBRYD dose to the original level in 14 days [see *Drug Interactions (7.5)*].

### **2.4 Discontinuing Treatment**

Discontinuation symptoms have been reported with discontinuation of serotonergic drugs such as VIIBRYD. Gradual dose reduction is recommended, instead of abrupt discontinuation, whenever possible. Monitor patients for these symptoms when discontinuing VIIBRYD. If intolerable symptoms occur following a dose decrease or upon discontinuation of treatment, consider resuming the previously prescribed dose and decreasing the dose at a more gradual rate [see *Warnings and Precautions (5.6)*].

### **2.5 Switching a Patient To or From a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders**

At least 14 days should elapse between discontinuation of an MAOI intended to treat psychiatric disorders and initiation of therapy with VIIBRYD. Conversely, at least 14 days should be allowed after stopping VIIBRYD before starting an MAOI intended to treat psychiatric disorders [see *Contraindications (4.1)*].

### **2.6 Use of VIIBRYD with Other MAOIs such as Linezolid or Methylene Blue**

Do not start VIIBRYD in a patient who is being treated with linezolid or intravenous methylene blue because there is an increased risk of serotonin syndrome. In a patient who requires more urgent treatment of a psychiatric condition, other interventions, including hospitalization, should be considered [see *Contraindications (4.1)*].

In some cases, a patient already receiving VIIBRYD therapy may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin syndrome in a particular patient, VIIBRYD should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for symptoms of serotonin syndrome for 2 weeks or until 24 hours after the last dose of linezolid or intravenous methylene blue, whichever comes first. Therapy with VIIBRYD may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue [see *Warnings and Precautions (5.2)*].

The risk of administering methylene blue by non-intravenous routes (such as oral tablets or by local injection) or in intravenous doses much lower than 1 mg/kg with VIIBRYD is unclear. The clinician should, nevertheless, be aware of the possibility of emergent symptoms of serotonin syndrome with such use [see *Warnings and Precautions (5.2)*].

### 3 DOSAGE FORMS AND STRENGTHS

VIIBRYD Tablets are available as 10 mg, 20 mg and 40 mg immediate-release, film-coated tablets.

- 10 mg pink, oval tablet, debossed with 10 on one side
- 20 mg orange, oval tablet, debossed with 20 on one side
- 40 mg blue, oval tablet, debossed with 40 on one side

### 4 CONTRAINDICATIONS

#### 4.1 Monoamine Oxidase Inhibitors (MAOIs)

The use of MAOIs intended to treat psychiatric disorders with VIIBRYD or within 14 days of stopping treatment with VIIBRYD is contraindicated because of an increased risk of serotonin syndrome. The use of VIIBRYD within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated [see *Dosage and Administration (2.5)*, and *Warnings and Precautions (5.2)*].

Starting VIIBRYD in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see *Dosage and Administration (2.6)*, and *Warnings and Precautions (5.2)*].

### 5 WARNINGS AND PRECAUTIONS

#### 5.1 Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults

Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a long-standing concern, however, that

antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled studies of antidepressant drugs (selective serotonin reuptake inhibitors [SSRIs] and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18-24) with MDD and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.

The pooled analyses of placebo-controlled studies in children and adolescents with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term studies of 9 antidepressant drugs in over 4,400 patients. The pooled analyses of placebo-controlled studies in adults with MDD or other psychiatric disorders included a total of 295 short-term studies (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs. placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1000 patients treated) are provided in **Table 1**.

**Table 1:**

Age Range	Drug-Placebo Difference in Number of Cases of Suicidality per 1000 Patients Treated
	<b>Increases Compared to Placebo</b>
<18	14 additional cases
18-24	5 additional cases
	<b>Decreases Compared to Placebo</b>
25-64	1 fewer case
≥65	6 fewer cases

No suicides occurred in any of the pediatric studies. There were suicides in the adult studies, but the number was not sufficient to reach any conclusion about drug effect on suicide.

It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance studies in adults with depression that the use of antidepressants can delay the recurrence of depression.

**All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.**

The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.

Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.

If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms [*see Warnings and Precautions (5.6) and Dosage and Administration (2.4)*].

**Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to healthcare providers. Such monitoring should include daily observation by families and caregivers. Prescriptions for VIIBRYD should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose [*see also Patient Counseling Information (17.1)*].**

#### Screening patients for bipolar disorder

A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled studies) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. It should be noted that VIIBRYD is not approved for use in treating bipolar depression.

## 5.2 Serotonin Syndrome

The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including VIIBRYD, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue). Symptoms of serotonin syndrome were noted in 0.1% of MDD patients treated with VIIBRYD in premarketing clinical trials

Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome.

The concomitant use of VIIBRYD with MAOIs intended to treat psychiatric disorders is contraindicated. VIIBRYD should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses. There may be circumstances when it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking VIIBRYD. VIIBRYD should be discontinued before initiating treatment with the MAOI [*see Contraindications (4.1) and Dosage and Administration (2.5 and 2.6)*].

If concomitant use of VIIBRYD with other serotonergic drugs including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan and St. John's Wort is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases.

Treatment with VIIBRYD and any concomitant serotonergic agents, should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.

## 5.3 Seizures

VIIBRYD has not been systematically evaluated in patients with a seizure disorder. Patients with a history of seizures were excluded from clinical studies. Like other antidepressants, VIIBRYD should be prescribed with caution in patients with a seizure disorder.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.